Seffalair Spiromax: Uses, Dosage & Side Effects

What Is Seffalair Spiromax and What Is It Used For?

Seffalair Spiromax contains two active substances that work together to manage chronic asthma: salmeterol (as salmeterol xinafoate) and fluticasone propionate. These two drugs belong to different pharmacological classes and have complementary mechanisms of action. This is why they are combined into a single inhaler — to address both the underlying inflammation of asthma and the bronchoconstriction that causes symptoms, with a single convenient device and consistent dosing schedule.

Fluticasone propionate is a highly potent synthetic glucocorticoid that acts locally in the airways to suppress inflammation. When inhaled twice daily, fluticasone propionate binds to intracellular glucocorticoid receptors and modulates the transcription of numerous genes involved in the inflammatory response. The net effect is a reduction in the production of pro-inflammatory cytokines, chemokines, and leukotrienes; decreased recruitment and activation of eosinophils, mast cells, T lymphocytes, and macrophages into the airway wall; decreased microvascular leakage and mucus hypersecretion; and reduced airway hyperresponsiveness to environmental triggers. These anti-inflammatory effects develop gradually over days to weeks of regular use, which is why Seffalair Spiromax must be taken every day, even when the patient feels well. Fluticasone propionate has very high topical potency combined with extensive first-pass hepatic metabolism (more than 99%), which minimizes systemic exposure when the drug is inhaled properly.

Salmeterol is a selective, long-acting beta2-adrenergic agonist. Its elongated lipophilic side chain anchors the molecule within the cell membrane adjacent to the beta2-adrenergic receptor, where it produces a prolonged receptor interaction. Stimulation of the beta2-receptor activates adenylyl cyclase, elevates intracellular cyclic adenosine monophosphate (cAMP) levels, and relaxes bronchial smooth muscle. The result is sustained bronchodilation — a widening of the airway lumen that facilitates airflow — lasting at least 12 hours. Unlike the fast-onset LABA formoterol, salmeterol has a slower onset of action (10–20 minutes to full effect), which is clinically important: Seffalair Spiromax is suitable only for maintenance therapy and cannot be used as a reliever during an acute asthma attack.

The pharmacological rationale for combining an ICS with a LABA is well established in international asthma treatment guidelines. The fluticasone propionate component targets the underlying inflammatory process, while salmeterol maintains open airways throughout the day and night. Large randomized controlled trials have demonstrated that ICS/LABA combination therapy produces greater improvements in lung function, symptom control and quality of life — and fewer exacerbations — than the equivalent dose of ICS alone in patients with persistent asthma who remain symptomatic on a moderate ICS dose. The Global Initiative for Asthma (GINA) 2024 report and national guidelines such as the British National Formulary (BNF) and NICE asthma guideline recommend ICS/LABA combinations as a cornerstone of step-up treatment for persistent asthma not controlled by ICS monotherapy.

Indications

Seffalair Spiromax is indicated for the regular treatment of asthma in patients aged 12 years and older, where the use of a combination product (an inhaled corticosteroid and a long-acting beta2-agonist) is appropriate. This applies in two main clinical scenarios:

• Patients not adequately controlled with inhaled corticosteroids and as-needed short-acting beta2-agonists. When low-to-moderate dose ICS alone fails to achieve or maintain good asthma control — for example, in patients with ongoing daytime symptoms, night-time awakenings, frequent use of reliever inhalers, or activity limitation — adding a LABA in a fixed-dose combination is an evidence-based step-up option.
• Patients already adequately controlled on both an inhaled corticosteroid and a long-acting beta2-agonist. A fixed-dose combination such as Seffalair Spiromax can simplify the regimen, improve adherence, and guarantee that the LABA is never taken without concomitant ICS.

Seffalair Spiromax is not indicated for the initial management of asthma and is not suitable for patients with only intermittent or mild symptoms that can be controlled with a short-acting reliever or a low-dose ICS. Regulatory labels outside the European Union may differ; the Spiromax salmeterol/fluticasone combination is marketed in some regions (for example, AirDuo RespiClick in the United States) with similar indications.

The Spiromax Device

Seffalair Spiromax is delivered via the Spiromax inhaler, a multi-dose, breath-actuated dry powder inhaler (DPI). The device was designed with inhaler-handling errors in mind. Common errors with conventional DPIs include failing to prepare the dose correctly, shaking the device, exhaling into the mouthpiece, and inhaling too slowly. The Spiromax addresses these pitfalls through a simple three-step operation — open the mouthpiece cover, breathe in deeply and forcefully, close the cover — with the dose loaded automatically when the cover is opened. The device contains 60 metered doses, has a dose counter on the back that counts down from 60, and delivers a consistent dose across a wide range of inspiratory flow rates. Studies of the Spiromax device have demonstrated a lower rate of critical inhaler technique errors compared with some other dry powder inhalers, which is particularly relevant for adolescents and older adults who may have difficulty with more complex devices.

What Should You Know Before Taking Seffalair Spiromax?

Seffalair Spiromax is a potent combination therapy, and a careful pre-treatment assessment is essential to ensure the benefits outweigh any risks. Before your first prescription, your doctor will review your asthma control, your current medications, your medical history, and any relevant laboratory results. The following information outlines the main safety considerations for patients starting or continuing Seffalair Spiromax.

Contraindications

Seffalair Spiromax must not be used in the following situations:

• Known hypersensitivity to salmeterol, fluticasone propionate, or any of the excipients, including lactose monohydrate (which contains small amounts of milk protein). Patients with a documented severe milk-protein allergy should not use this inhaler.
• As sole therapy for asthma — the LABA component (salmeterol) must never be used without a concomitant inhaled corticosteroid, due to an increased risk of severe asthma-related events when LABAs are used as monotherapy.
• For the rapid relief of acute bronchospasm or during an asthma exacerbation. Salmeterol has a slower onset of action than a short-acting beta2-agonist and is not suitable for emergency use.
• In children under 12 years of age, since safety and efficacy of the 12.75/100 mcg Spiromax strength have not been established in this age group. Other salmeterol/fluticasone formulations are available for pediatric use.

Warnings and Precautions

Your doctor should be aware of the following conditions before you start Seffalair Spiromax, as they may require special monitoring or dose adjustment:

• Cardiovascular disease. Salmeterol, like all beta2-agonists, can cause tachycardia, palpitations, and in rare cases, arrhythmias. Patients with a history of ischemic heart disease, arrhythmias, severe hypertension, or hypertrophic obstructive cardiomyopathy should be monitored.
• Diabetes mellitus. High doses of beta2-agonists may elevate blood glucose levels. Monitoring is recommended in patients with diabetes.
• Thyroid disease. Hyperthyroidism may potentiate the cardiovascular effects of salmeterol.
• Hypokalemia. Beta2-agonists may cause potentially serious low potassium levels, particularly in combination with other potassium-lowering drugs (e.g., loop or thiazide diuretics, xanthines, systemic corticosteroids) or in severe asthma where concomitant therapies are common.
• Tuberculosis and respiratory infections. Inhaled corticosteroids may mask or worsen latent or active pulmonary tuberculosis and fungal or viral respiratory infections. Patients with a history of TB require careful evaluation.
• Liver impairment. Fluticasone propionate is extensively metabolized in the liver, so systemic exposure may be increased in severe hepatic impairment.
• Paradoxical bronchospasm. In rare cases, inhalation of the dry powder may provoke a sudden worsening of wheezing and shortness of breath. If this occurs, the patient must stop Seffalair Spiromax immediately, use a fast-acting reliever inhaler, and seek medical attention.
• Worsening asthma. An increase in the need for a reliever inhaler, reduced response to the reliever, or a fall in morning peak flow are all warning signs of deteriorating control. Patients should not increase the dose of Seffalair Spiromax themselves but should contact their doctor promptly.
• Systemic corticosteroid effects. As with all inhaled corticosteroids, especially at high doses and over prolonged periods, systemic effects such as adrenal suppression, reduced bone mineral density, growth retardation in adolescents, cataracts and glaucoma may occur. The lowest effective dose should be used.

Pregnancy and Breastfeeding

Asthma control during pregnancy is critically important for both maternal and fetal health. Uncontrolled asthma is associated with preterm birth, low birth weight, pre-eclampsia, and other adverse outcomes, whereas well-controlled asthma in pregnancy generally produces outcomes similar to women without asthma. Seffalair Spiromax should therefore be used during pregnancy only when the expected benefit to the mother outweighs any potential risk to the fetus. Large observational studies and pregnancy registries of inhaled corticosteroids (including fluticasone propionate) and inhaled salmeterol have not identified a clinically meaningful increase in the risk of major congenital malformations or adverse pregnancy outcomes. Where a change in therapy is considered during pregnancy, it is generally safer to continue an established, effective regimen than to destabilize asthma control.

During breastfeeding, small amounts of both fluticasone propionate and salmeterol may be excreted in breast milk, but systemic concentrations after inhalation are low and clinically significant effects on the infant are not expected. The decision to continue or discontinue therapy should balance the benefit of breastfeeding for the infant with the benefit of asthma control for the mother. Women planning pregnancy or who are pregnant or breastfeeding should discuss their treatment with their healthcare provider and, where available, enroll in national pregnancy registries for asthma medications.

Elderly Patients, Renal and Hepatic Impairment

No dose adjustment of Seffalair Spiromax is required in elderly patients based on age alone. However, elderly patients may be more susceptible to the systemic effects of inhaled corticosteroids (e.g., osteoporosis, cataracts, skin thinning) and the cardiovascular effects of beta2-agonists (e.g., tachycardia, tremor). Clinicians should consider periodic bone density assessment, ophthalmologic examination, and blood pressure monitoring in long-term use. No specific dose adjustment is recommended in renal impairment. In severe hepatic impairment, systemic exposure to fluticasone propionate may be increased, so the potential for systemic corticosteroid effects should be considered.

Driving and Operating Machinery

Seffalair Spiromax is not expected to affect the ability to drive or operate machinery. However, uncontrolled asthma symptoms may impair alertness and performance. Rarely, side effects such as dizziness, tremor, or palpitations could interfere with driving; patients who experience such symptoms should not drive or operate machinery until the symptoms resolve.

How Does Seffalair Spiromax Interact with Other Drugs?

Although inhaled medications produce lower systemic drug levels than oral or injected forms, clinically significant drug interactions with Seffalair Spiromax do occur. The interactions involve mainly the hepatic metabolism of fluticasone propionate and the cardiovascular and metabolic effects of salmeterol. The table below summarizes the most relevant interactions; this is not an exhaustive list, and healthcare professionals should consult prescribing information and up-to-date drug interaction resources before prescribing.

Major Interactions

Minor Interactions and Considerations

Always provide your healthcare provider and pharmacist with a complete list of prescription medications, over-the-counter products, vitamins, and herbal supplements you are taking or plan to take. Herbal products such as St. John's wort (a CYP3A4 inducer) can theoretically reduce fluticasone exposure, and certain weight-loss or sports supplements may contain sympathomimetic stimulants that could add to the cardiovascular effects of salmeterol.

What Is the Correct Dosage of Seffalair Spiromax?

The dosage of Seffalair Spiromax is individualized by the treating physician based on disease severity, current asthma control, previous treatment, and response to therapy. The goal is to achieve and maintain asthma control with the lowest effective dose. The following information summarizes the usual recommended dosage; always follow the specific instructions given by your prescribing physician and the patient information leaflet that accompanies your inhaler.

Adults (18 Years and Older)

After treatment is started, patients should be reassessed regularly (typically every 3 months). Once asthma control has been achieved and maintained, the physician may consider stepping down therapy — for example, by reducing to a lower ICS strength or switching back to ICS monotherapy — to identify the minimum effective treatment. Stepping down should not be attempted during periods of infection, uncontrolled symptoms, or seasonal exacerbations.

Adolescents (12–17 Years)

Seffalair Spiromax 12.75/100 mcg may be used in adolescents aged 12 to 17 years at the same dose as adults: one inhalation twice daily. Growth of adolescents on long-term inhaled corticosteroids should be monitored periodically. If growth is slowed, the dose should be reviewed to ensure it is the lowest effective dose needed to maintain control. Adolescents should be educated on inhaler technique and the importance of adherence, and should be involved in creating a written asthma action plan.

Children Under 12 Years

Seffalair Spiromax 12.75/100 mcg is not recommended for children under 12 years of age, as safety and efficacy have not been established in this population. Alternative salmeterol/fluticasone formulations (for example, fluticasone propionate 100 mcg / salmeterol 50 mcg delivered via Diskus) are approved for use in children aged 4–11 years at lower doses and should be prescribed when appropriate. Pediatric asthma should be managed by a clinician with appropriate expertise.

Elderly Patients

No dose adjustment is required solely on the basis of age. However, elderly patients may be more vulnerable to systemic corticosteroid effects (reduced bone density, skin thinning, cataracts, glaucoma) and to cardiovascular effects of beta2-agonists. A starting dose at the lower end of the range and regular review are advisable.

Patients with Renal or Hepatic Impairment

There are no specific dosing recommendations in renal impairment. In severe hepatic impairment, systemic exposure to fluticasone propionate may be increased; clinicians should weigh the benefits against the potential for systemic corticosteroid effects and consider using the lowest effective dose with additional monitoring.

Missed Dose

If you forget to take a dose of Seffalair Spiromax, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and continue with your usual schedule. Never take a double dose to make up for a forgotten one. Consistent daily use is essential for maintaining asthma control; consider setting a daily alarm or using a medication reminder app, and always keep a spare inhaler on hand.

Overdose

An overdose of Seffalair Spiromax is likely to produce exaggerated beta2-agonist effects: tremor, headache, tachycardia, palpitations, elevated blood pressure, muscle cramps, and metabolic changes (hypokalemia, hyperglycemia, metabolic acidosis). Very high doses of inhaled fluticasone propionate are unlikely to cause acute clinical problems, but chronic overdose can lead to systemic corticosteroid effects, including adrenal suppression. Treatment of overdose is supportive and symptomatic; there is no specific antidote. Serum potassium levels should be monitored and corrected as needed. If you suspect an overdose, contact your doctor, pharmacist, emergency services, or a poison control center immediately.

How to Use the Spiromax Inhaler

Correct inhaler technique is essential for Seffalair Spiromax to work effectively. The Spiromax is a breath-actuated dry powder inhaler, so the dose is released automatically as you breathe in. Follow these steps carefully for each inhalation:

1. Hold the inhaler upright with the mouthpiece cover at the bottom. Do not shake the inhaler.
2. Open: Fold the mouthpiece cover all the way down until you hear a click. This loads one dose and the dose counter decreases by one. Do not open and close the cover unnecessarily, as this may waste doses.
3. Breathe out gently, away from the mouthpiece. Do not exhale into the device — moisture can clump the powder and reduce dose delivery.
4. Inhale: Place the mouthpiece between your lips, seal your lips firmly around it, and inhale deeply and forcefully through the mouth. The powder is tasteless and odorless, so you may not feel the dose — this is normal.
5. Hold your breath for approximately 10 seconds, or as long as is comfortable, to allow the medication to settle in the airways.
6. Close: Breathe out gently through the nose and close the mouthpiece cover.
7. Rinse your mouth with water and spit it out (do not swallow) to reduce the risk of oral thrush and hoarseness.

What Are the Side Effects of Seffalair Spiromax?

Like all medicines, Seffalair Spiromax can cause side effects, although not everyone experiences them. Most side effects are related to the known class effects of inhaled corticosteroids (local deposition effects, systemic effects at high doses) or beta2-agonists (tremor, palpitations, metabolic effects). The following list is organized by frequency according to the standard Medical Dictionary for Regulatory Activities (MedDRA) classification used in the Summary of Product Characteristics.

Oral candidiasis (thrush) is the most commonly reported local side effect of inhaled corticosteroids. It occurs because residual corticosteroid in the mouth and throat suppresses local immune defenses, allowing the yeast Candida albicans to overgrow. The risk can be substantially reduced by rinsing the mouth with water after every inhalation and spitting the water out; using the inhaler before meals (so that eating and drinking afterwards rinse residual powder) can also help. If thrush develops, it is usually easily treated with an antifungal mouthwash (for example, nystatin) or oral antifungal medication prescribed by your doctor.

Hoarseness (dysphonia) and throat irritation are also common local effects. They are caused by deposition of the dry powder on the vocal cords and pharynx, and are usually reversible when the inhaler is temporarily discontinued or when technique is corrected. A gentle clearing of the throat, slow warm-up of the voice, and mouth-rinsing after each dose are helpful strategies. Professional voice users should discuss any persistent voice changes with their doctor.

Tremor and palpitations are known class effects of beta2-agonists. They are typically mild, dose-related, and diminish with regular use as the body develops tolerance. If these symptoms are bothersome, or if you experience chest pain, irregular heartbeat, or severe dizziness, seek medical attention promptly. Long-term use of any inhaled corticosteroid, especially at high doses, warrants regular review of bone density, blood pressure, eye health, and, in children and adolescents, growth velocity.

How Should You Store Seffalair Spiromax?

Proper storage is essential to preserve the quality, stability and delivered dose of Seffalair Spiromax. Because it is a dry powder inhaler, the medication is particularly sensitive to moisture, which can cause the powder to clump and reduce the amount actually inhaled. Follow these storage guidelines to ensure reliable dosing:

• Temperature: Store below 25°C (77°F). Avoid direct sunlight, radiators, and other heat sources. Refrigeration is not required and not recommended.
• Do not freeze: Freezing can damage the inhaler mechanism and impair dose delivery.
• Protect from moisture: Always keep the mouthpiece cover closed when the inhaler is not in use. Do not store the inhaler in bathrooms or other humid environments, and avoid placing it in the freezer of a fridge or a damp bag.
• Keep out of reach of children: Store Seffalair Spiromax in a safe location where young children and pets cannot access it. Accidental inhalation by children can cause significant cardiovascular and endocrine effects.
• Expiration date: Do not use Seffalair Spiromax after the expiration date printed on the label and carton. The expiration date refers to the last day of the indicated month.
• Shelf life after first opening: Once the foil pouch (if applicable) has been opened, use the inhaler within the timeframe specified on the packaging — typically within three months.
• Disposal: Do not dispose of the inhaler in household waste. Return unused or expired medication to your pharmacist, who will ensure safe disposal in accordance with local regulations and environmental protection rules.

When traveling with Seffalair Spiromax, keep it in your hand luggage where the temperature is more controlled. Do not leave it in a parked car in hot weather, as the interior temperature can rise well above 40°C and compromise the medicine. If you travel to a tropical or very humid climate, consider carrying the inhaler in a sealed plastic bag or a small, airtight pouch for additional moisture protection. Always carry a copy of your prescription and enough medication to cover your entire trip plus a buffer in case of delays.

What Does Seffalair Spiromax Contain?

Active Ingredients

Seffalair Spiromax contains two active substances that work together to treat asthma:

Lactose monohydrate is a sugar derived from milk and is widely used as a carrier in dry powder inhalers. It helps the fine drug particles flow through the device and deposit consistently in the airways. The quantity of lactose per inhalation is very small, and the amount of milk protein present is even smaller; nevertheless, patients with clinically significant milk-protein allergy (not ordinary lactose intolerance) should discuss this with their doctor before using Seffalair Spiromax.

Appearance and Pack Sizes

Seffalair Spiromax is a white to off-white inhalation powder contained within a white plastic Spiromax inhaler with a colored semi-transparent mouthpiece cover (color may vary by market). Each inhaler contains 60 delivered doses and features a dose counter on the back panel that counts down from 60 to 0. Seffalair Spiromax is typically supplied in cartons of 1, 2, or 3 inhalers, though not all pack sizes may be marketed in every country.

Marketing Authorization and Regulatory Status

The salmeterol/fluticasone propionate Spiromax combination is developed and manufactured by Teva Pharmaceuticals. In the European Union it is marketed under brand names including Seffalair Spiromax; in the United States the corresponding product is marketed as AirDuo RespiClick. The Spiromax combination has been assessed by national regulatory authorities for pharmaceutical equivalence and in vitro comparability to the fluticasone/salmeterol Diskus device. Patients switching between different devices (for example, from Diskus or Evohaler to Spiromax) should receive device-specific training, as technique and inspiratory flow requirements differ between DPIs.